Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

8.860 +0.310 (+3.63%)
Streaming Delayed Price Updated: 3:53 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MeiraGTx Holdings plc - Ordinary Shares

< Previous 1 2 Next >
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms 
From MeiraGTx
Via GlobeNewswire
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy 
From MeiraGTx
Via GlobeNewswire
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
From MeiraGTx
Via GlobeNewswire
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary... 
From MeiraGTx
Via GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms 
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency 
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
From MeiraGTx
Via GlobeNewswire
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
From MeiraGTx
Via GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of... 
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
From MeiraGTx
Via GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions
Best Growth Stocks, a leading independent research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a... 
Via TheNewswire.com
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
Multiple Posters and Oral Presentations Highlight the Depth of Innovation from MeiraGTx’s Technology Platforms for Gene and Cell Therapy 
From MeiraGTx
Via GlobeNewswire
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapy 
From MeiraGTx
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.